Terry L. Evans, Chief Commercial Officer of Fennec Pharmaceuticals Inc., filed a Form 4 on November 2, 2026, reporting the release of 168 restricted common shares on October 31, 2026.

Key Highlights

  • Reporting person: Terry L. Evans, Chief Commercial Officer of Fennec Pharmaceuticals Inc. (NASDAQ:FENC)
  • Transaction date: October 31, 2026
  • Shares acquired: 168 common shares released from restriction, at a price of $0
  • Origin of shares: According to the filing, the shares were "released from restriction from shares awarded 3/28/2025"
  • Resulting ownership: 24,181 common shares held directly following the transaction
  • No derivative securities: Table II reports no derivative security transactions

Evans RSU Vesting Details for Fennec Pharmaceuticals

According to the Form 4 filed with the SEC on November 2, 2026, Terry L. Evans, who serves as Chief Commercial Officer of Fennec Pharmaceuticals Inc. (NASDAQ:FENC), reported an acquisition of 168 common shares on October 31, 2026. The transaction code listed is "A" (acquired), and the price recorded is $0, consistent with the nature of a restricted stock unit vesting event rather than an open-market purchase.

The filing's footnote states that the 168 shares represent shares "released from restriction from shares awarded 3/28/2025," identifying this as the vesting of a prior equity award. Following the reported transaction, Evans directly holds 24,181 common shares of Fennec Pharmaceuticals, as disclosed in Table I of the filing. No indirect ownership or derivative security positions are reported in connection with this filing.

The Form 4 was filed by one reporting person, with Evans signing the document on November 2, 2026. The filing does not indicate that a Rule 10b5-1(c) trading plan was in place for this transaction, and no amendment date is listed, indicating this is an original filing.

What Was Disclosed

The filing discloses a single non-derivative transaction: 168 common shares of Fennec Pharmaceuticals Inc. vested and were released from restriction for Chief Commercial Officer Terry L. Evans on October 31, 2026, bringing his direct beneficial ownership to 24,181 shares.